Biotech Values

[turtlepower]

ARRY - The melanoma data was expected end of june according to one analyst so i presumed the run up was due to that. I'm surprised the pain trial results caused a 15 % drop. The only reason I can think of is that 797 is fully owned and perhaps there was the possibility that it could also be faster to market than any of the other drugs.